Clinical Trials Logo

Vasculitis clinical trials

View clinical trials related to Vasculitis.

Filter by:

NCT ID: NCT06321601 Not yet recruiting - Vasculitis Clinical Trials

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV

Start date: July 31, 2024
Phase: Phase 3
Study type: Interventional

The main objective of this study is to explore the efficacy of avacopan in participants affected by AAV.

NCT ID: NCT06316076 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

Start date: October 30, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the safety and efficacy of CD19-CAR-DNT cells in subjects with relapsed/refractory autoimmune diseases

NCT ID: NCT06294236 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

Start date: April 2024
Phase: Phase 1
Study type: Interventional

SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.

NCT ID: NCT06285279 Recruiting - Lupus Nephritis Clinical Trials

FKC288 in Participants With Autoimmune Kidney Diseases

Start date: March 15, 2024
Phase: Phase 1
Study type: Interventional

This study is a single-center, open-label, dose-escalation exploratory clinical trial, expected to enroll 6 to 12 participants. It will use a BOIN (Bayesian Optimal Interval) design for dose escalation, with four predetermined dose groups (0.3×10^6 cells/kg, 1.0×10^6 cells/kg, 3.0×10^6 cells/kg, and an alternative dose of 0.1×10^6 cells/kg). Each dose group plans to enroll 1-2 or 3-6 participants with relapsed or refractory autoimmune-mediated kidney diseases (such as lupus nephritis, ANCA-associated vasculitis, membranous nephropathy, and IgG4-related diseases).

NCT ID: NCT06277427 Recruiting - Lupus Nephritis Clinical Trials

Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

Start date: February 5, 2024
Phase: N/A
Study type: Interventional

Lupus nephritis (LN) and ANCA-associated vasculitis are severe autoimmune diseases, which may lead to the death of patients, particularly when they are refractory to the conventional therapeutic agents. Based on the current knowledge, the autoantibodies against self-antigens may exert important pathological roles in the pathogenesis of both LN and ANCA-associated vasculitis, of which the origins are primarily plasmablasts and plasma cells. BCMA is the molecule expressed on memory B cells, plasmablasts and plasma cells, and therefore is an ideal target for the elimination of potential pathogenic antibody secreting cells. Chimeric antigen receptor (CAR) T cells against BCMA may provide a novel therapeutic way for the refractory LN and ANCA-associated vasculitis patients to eliminate the pathogenic autoantibody-secreting cells. In this study, the safety and efficacy of a novel CAR-T cell therapy using PRG-1801 cells, are evaluated in patients with refractory LN and ANCA-associated vasculitis.

NCT ID: NCT06266247 Active, not recruiting - Inflammation Clinical Trials

How Sirtuin Levels Change During Behçet Disease

Start date: January 15, 2024
Phase: N/A
Study type: Interventional

Our primary aim in our study is to evaluate the relationship between the activity, which will be evaluated by clinical and standard phase reactants, and the IL-6 and TNF-α levels, which will be measured in serum, in Behçet&#39;s patients. Our secondary aim was to evaluate Sirtuin-1 in Behcet&#39;s patients and compare it with the normal population. Our third aim is to find out whether there is a relationship between these values and organ involvement.

NCT ID: NCT06244069 Not yet recruiting - Clinical trials for Giant Cell Arteritis

Clonal Hematopoiesis in Giant Cell Arteritis

CH-GCA
Start date: March 2024
Phase:
Study type: Observational

The goal of this clinical trial is to verify whether CHIP is correlated with the clinical, instrumental, and histological characteristics of GCA, and to characterize the pathogenetic effects of clonal hemopoiesis on vasculitis. The main objective of this study is to verify if clonal hematopoiesis of indeterminate potential (CHIP) affects GCA manifestations, course/response to therapies, and pathogenesis. Patients who are going to be diagnosed with GCA and for which a fast track is available for a rapid diagnostic work-up including pre-treatment temporal artery biopsy. Patients with CHIP will be identified and characterized by using whole exome sequencing from the peripheral blood samples. The presence and characteristics of CHIP will be correlated with baseline clinical, instrumental, and histologic GCA features.

NCT ID: NCT06226662 Not yet recruiting - Clinical trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Study of NM8074 in Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)

Start date: June 2025
Phase: Phase 2
Study type: Interventional

This is a Randomized, Double-Blind, Placebo-Controlled Study designed to assess safety, tolerability, and efficacy of NM8074 in AAV patients when used in combination with Standard of Care (SOC) cyclophosphamide/azathioprine or rituximab plus corticosteroids.

NCT ID: NCT06196905 Recruiting - Clinical trials for Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)

An Exploratory Study of MT-2990 in Patients With AAV

Start date: January 2024
Phase: Phase 1
Study type: Interventional

To explore the efficacy, safety, pharmacokinetics and mechanism of action of MT-2990 in patients with AAV.

NCT ID: NCT06152172 Not yet recruiting - Clinical trials for Diffuse Cutaneous Systemic Sclerosis

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

CARTIMMUNE
Start date: February 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive 1 dose of KYV-101 and will be followed for 2 years.